Incyte Stock Performance
| INCY Stock | USD 70.42 0.41 0.59% |
The company retains a Market Volatility (i.e., Beta) of 0.39, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, Incyte's returns are expected to increase less than the market. However, during the bear market, the loss of holding Incyte is expected to be smaller as well. Incyte right now retains a risk of 2.01%. Please check out Incyte treynor ratio, as well as the relationship between the accumulation distribution and price action indicator , to decide if Incyte will be following its current trending patterns.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Incyte has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly strong fundamental indicators, Incyte is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors. ...more
Actual Historical Performance (%)
One Day Return 0.59 | Five Day Return 6.21 | Year To Date Return 1.28 | Ten Year Return (9.49) | All Time Return 3.7 K |
Last Split Factor 2:1 | Last Split Date 2000-09-01 |
1 | Acquisition by Trotta Matteo of 2646 shares of Incyte subject to Rule 16b-3 | 11/22/2024 |
2 | Disposition of 4961 shares by Herve Hoppenot of Incyte at 64.25 subject to Rule 16b-3 | 11/29/2024 |
3 | Acquisition by Harrigan Edmund of 3 shares of Incyte at 69.07 subject to Rule 16b-3 | 12/31/2024 |
4 | Acquisition by Issa Mohamed Khairie of 48671 shares of Incyte subject to Rule 16b-3 | 01/08/2025 |
5 | Innovent Receives NMPA Breakthrough Therapy Designation for IBI343 as Monotherapy for Advanced Pancreatic Cancer | 01/16/2025 |
6 | Acquisition by Flannelly Barry P of 20144 shares of Incyte at 71.93 subject to Rule 16b-3 | 01/22/2025 |
7 | CX Institutional Grows Stake in Incyte Co. | 01/27/2025 |
8 | Curious about Incyte Q4 Performance Explore Wall Street Estimates for Key Metrics | 02/05/2025 |
9 | Incyte Corp Announces Grant of Restricted Stock Units to New Employees | 02/07/2025 |
10 | Incyte Reports 2024 Financial Results and Outlines 2025 Projections | 02/10/2025 |
11 | Incyte price target lowered by 9 at Citi, heres why INCY | 02/11/2025 |
12 | Citigroup Issues Pessimistic Forecast for Incyte Stock Price | 02/13/2025 |
13 | Incyte Co. Shares Acquired by Catalyst Financial Partners LLC | 02/14/2025 |
| Begin Period Cash Flow | 3.2 B |
Incyte |
Incyte Relative Risk vs. Return Landscape
If you would invest 7,056 in Incyte on November 19, 2024 and sell it today you would lose (14.00) from holding Incyte or give up 0.2% of portfolio value over 90 days. Incyte is currently generating 0.0168% in daily expected returns and assumes 2.0092% risk (volatility on return distribution) over the 90 days horizon. In different words, 17% of stocks are less volatile than Incyte, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Incyte Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Incyte's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Incyte, and traders can use it to determine the average amount a Incyte's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0084
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | INCY |
Estimated Market Risk
| 2.01 actual daily | 17 83% of assets are more volatile |
Expected Return
| 0.02 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| 0.01 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Incyte is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Incyte by adding Incyte to a well-diversified portfolio.
Incyte Fundamentals Growth
Incyte Stock prices reflect investors' perceptions of the future prospects and financial health of Incyte, and Incyte fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Incyte Stock performance.
| Return On Equity | 0.0075 | ||||
| Return On Asset | 0.0086 | ||||
| Profit Margin | 0.01 % | ||||
| Operating Margin | 0.25 % | ||||
| Current Valuation | 11.51 B | ||||
| Shares Outstanding | 193.52 M | ||||
| Price To Earning | 19.17 X | ||||
| Price To Book | 3.95 X | ||||
| Price To Sales | 3.21 X | ||||
| Revenue | 4.24 B | ||||
| Gross Profit | 1.48 B | ||||
| EBITDA | 408.16 M | ||||
| Net Income | 32.62 M | ||||
| Cash And Equivalents | 2.72 B | ||||
| Cash Per Share | 12.24 X | ||||
| Total Debt | 37.96 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 3.91 X | ||||
| Book Value Per Share | 17.82 X | ||||
| Cash Flow From Operations | 335.34 M | ||||
| Earnings Per Share | 0.15 X | ||||
| Market Capitalization | 13.63 B | ||||
| Total Asset | 5.44 B | ||||
| Retained Earnings | (1.07 B) | ||||
| Working Capital | 1.6 B | ||||
| Current Asset | 842.38 M | ||||
| Current Liabilities | 168.01 M | ||||
About Incyte Performance
Evaluating Incyte's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Incyte has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Incyte has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 68.86 | 65.41 | |
| Return On Tangible Assets | 0.01 | 0.01 | |
| Return On Capital Employed | 0.02 | 0.02 | |
| Return On Assets | 0.01 | 0.01 | |
| Return On Equity | 0.01 | 0.01 |
Things to note about Incyte performance evaluation
Checking the ongoing alerts about Incyte for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Incyte help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Incyte has a strong financial position based on the latest SEC filings | |
| Over 97.0% of the company shares are owned by institutional investors | |
| Latest headline from thelincolnianonline.com: Incyte Co. Shares Acquired by Catalyst Financial Partners LLC |
- Analyzing Incyte's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Incyte's stock is overvalued or undervalued compared to its peers.
- Examining Incyte's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Incyte's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Incyte's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Incyte's stock. These opinions can provide insight into Incyte's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Incyte Stock Analysis
When running Incyte's price analysis, check to measure Incyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Incyte is operating at the current time. Most of Incyte's value examination focuses on studying past and present price action to predict the probability of Incyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Incyte's price. Additionally, you may evaluate how the addition of Incyte to your portfolios can decrease your overall portfolio volatility.